DHL Group has announced an investment of €2 billion over the next five years to enhance its logistics capabilities in the life sciences and healthcare sector.
The investment supports the Group’s Strategy 2030, and reinforces DHL’s commitment to helping healthcare customers grow, innovate and serve patients more effectively worldwide, says an official release. “With 50 percent of the investment allocated to the Americas, 25 percent to Asia Pacific and 25 percent to the EMEA region, DHL is expanding its global footprint to deliver integrated, faster, more reliable, and patient-centric logistics solutions wherever healthcare companies operate.”
A significant part of the investment will be allocated to establishing new cross-divisional GPD-certified pharma hubs for multi-temperature shipments lanes, expanding cold chain capacity in existing facilities, commissioning new temperature-controlled vehicles, and enhancing both passive and active packaging solutions to ensure sustainable delivery, the release added.
“As the demand grows in critical areas such as clinical trials, biopharma, and cell and gene therapies, DHL is also investing in high-quality, specialised cooling infrastructure to accommodate low and ultra-low temperature ranges. Additionally, the Group will implement cutting-edge IT systems that provide end-to-end visibility, ensuring product integrity, regulatory compliance, and confidence for healthcare providers and their patients.
“With its new sector brand DHL Health Logistics, the group consolidates its life sciences and healthcare expertise under one unified umbrella. This creates a seamless, end-to-end experience for customers, simplifying the management of complex, cross-border supply chains with confidence, agility and high-quality service. The approach is designed to meet the needs of pharmaceutical, biopharma and medical customers who require agile, connected logistics solutions that go beyond traditional service lines.”
With an additional €5 billion in projected incremental revenue by 2030, DHL Group is scaling its operations to match the fast-evolving needs of the industry and its end-users – healthcare professionals and patients alike, the release added. “Similar to DHL Group’s purpose of Connecting people, improving lives, our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” says Oscar de Bok, CEO, DHL Supply Chain. “We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create – ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.”
“Similar to DHL Group’s purpose of Connecting people, improving lives, our strategic investment in life sciences and healthcare is driven by our customers’ mission: delivering essential, often life-saving products to people in need,” says Oscar de Bok, CEO, DHL Supply Chain.
“We’re building high-quality, integrated logistics solutions that are as innovative and reliable as the products our customers create – ensuring that patients everywhere receive the right treatment, at the right time, with complete confidence.” DHL Group currently operates nearly 600 sites, hubs and warehouses across close to 130 countries dedicated to life sciences and healthcare logistics, encompassing a total of more than 2.5 million square metres of temperature-controlled warehouse space. DHL Group has recently acquired CRYOPDP, a leading specialty courier focused on clinical trials, biopharma and cell and gene therapies to further strengthen its capabilities in the segment, the release added.
The post DHL to invest €2 billion in DHL Health Logistics appeared first on Air Cargo Week.
